Empyema thoracis: New insights into an old disease

European Respiratory Review

Volumn 19, Issue 117, 2010, Pages 220-228

  Brims, F J H ^a,b   Lansley, S M ^c   Waterer, G W ^c   Lee, Y C G ^b,c  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Empyema; Infection; Mesothelial; Pleural; Pneumonia

Indexed keywords

ALTEPLASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFUROXIME; DEOXYRIBONUCLEASE; FIBRINOLYTIC AGENT; MEROPENEM; METRONIDAZOLE; PNEUMOCOCCUS VACCINE; STREPTOKINASE; VANCOMYCIN;

ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG CHOICE; ECHOGRAPHY; HUMAN; IMMUNE RESPONSE; LUNG FIBROSIS; MESOTHELIUM; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PLEURA EFFUSION; PLEURA EMPYEMA; PLEURA FLUID; PLEURISY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS MILLERI; STREPTOCOCCUS PNEUMONIAE; SURGICAL DRAINAGE; THORACOCENTESIS; THORACOTOMY; THORAX RADIOGRAPHY; VIDEO ASSISTED THORACOSCOPIC SURGERY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHEST TUBES; DRAINAGE; EMPYEMA, PLEURAL; HUMANS; PREVALENCE;

EID: 77957276812     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00005610     Document Type: Article

References (108)

1. Dunham EK, Graham EA, Mitchell JF et al, Empyema commission. Cases of empyema at Camp Lee, VA. Preliminary report. Am J Med Assoc 1918; 71: 366-373.
2. Davies CW, Kearney SE, Gleeson FV, et al. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999; 160: 1682-1687.
3. Ferguson AD, Prescott RJ, Selkon JB, et al. The clinical course and management of thoracic empyema. QJM 1996; 89: 285-289.
4. Maskell NA, Davies CW, Nunn AJ, et al. UK controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352: 865-874.
5. Desai G, Amadi W. Three years' experience of empyema thoracis in association with HIV infection. Trop Doct 2001; 31: 106-107.
6. Light RW, Rodriguez RM. Management of parapneumonic effusions. Clin Chest Med 1998; 19: 373-382.
7. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000; 118: 1158-1171.
8. Roxburgh CS, Youngson GG, Townend JA, et al. Trends in pneumonia and empyema in Scottish children in the past 25 years. Arch Dis Child 2008; 93: 316-318.
9. Hendrickson DJ, Blumberg DA, Joad JP, et al. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2008; 27: 1030-1032.
10. Munoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46: 174-182.
11. Van Ackere T, Proesmans M, Vermeulen F, et al. Complicated parapneumonic effusion in Belgian children: increased occurrence before routine pneumococcal vaccine implementation. Eur J Pediatr 2009; 168: 51-58.
12. Finley C, Clifton J, Fitzgerald JM, et al. Empyema: an increasing concern in Canada. Can Respir J 2008; 15: 85-89.
13. Chapman SJ, Khor CC, Vannberg FO, et al. IkappaB genetic polymorphisms and invasive pneumococcal disease. Am J Respir Crit Care Med 2007; 176: 181-187.
14. Rahman NM, Davies RJO. Effusions from infections: parapneumonic effusion and empyema. In: Light RW, Lee YCG eds. Textbook of Pleural Disease. 2nd Edn. London, Hodder Arnold, 2008; pp. 341-366.
15. Liapakis IE, Light RW, Pitiakoudis MS, et al. Penetration of clarithromycin in experimental pleural empyema model fluid. Respiration 2005; 72: 296-300.
16. Strahilevitz J, Lev A, Levi I, et al. Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. J Antimicrob Chemother 2003; 51: 665-669.
17. Shohet I, Yellin A, Meyerovitch J, et al. Pharmacokinetics and therapeutic efficacy of gentamicin in an experimental pleural empyema rabbit model. Antimicrob Agents Chemother 1987; 31: 982-985.
18. Sahn SA, Reller LB, Taryle DA, et al. The contribution of leukocytes and bacteria to the low pH of empyema fluid. Am Rev Respir Dis 1983; 128: 811-815.
19. Strange C, Allen ML, Harley R, et al. Intrapleural streptokinase in experimental empyema. Am Rev Respir Dis 1993; 147: 962-966.
20. Sasse SA, Causing LA, Mulligan ME, et al. Serial pleural fluid analysis in a new experimental model of empyema. Chest 1996; 109: 1043-1048.
21. Schopf LF, Fraga JC, Amantea SL, et al. Induction of pleural empyema in rats by thoracentesis with intrapleural pressure monitoring. Pediatr Surg Int 2004; 20: 515-519.
22. Sahn SA, Taryle DA, Good JT Jr. Experimental empyema. Time course and pathogenesis of pleural fluid acidosis and low pleural fluid glucose. Am Rev Respir Dis 1979; 120: 355-361.
23. Mavroudis C, Ganzel BL, Katzmark S, et al. Effect of hemothorax on experimental empyema thoracis in the guinea pig. J Thorac Cardiovasc Surg 1985; 89: 42-49.
24. Zeillemaker AM, Diepersloot RJ, Leguit P. Mesothelial cell activation by micro-organisms. Sepsis 2000; 3: 285-291.
25. Kinnaert P, De Wilde JP, Bournonville B, et al. Direct activation of human peritoneal mesothelial cells by heat-killed microorganisms. Ann Surg 1996; 224: 749-755.
26. Visser CE, Steenbergen JJ, Betjes MG, et al. Interleukin-8 production by human mesothelial cells after direct stimulation with staphylococci. Infect Immun 1995; 63: 4206-4209.
27. van Westreenen M, Pronk A, Diepersloot RJ, et al. Chlamydia trachomatis infection of human mesothelial cells alters proinflammatory, procoagulant, and fibrinolytic responses. Infect Immun 1998; 66: 2352-2355.
28. Visser CE, Brouwer-Steenbergen JJ, Schadee-Eestermans IL, et al. Ingestion of Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli by human peritoneal mesothelial cells. Infect Immun 1996; 64: 3425-3428.
29. Broaddus VC, Boylan AM, Hoeffel JM, et al. Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of endotoxin induced pleurisy. J Immunol 1994; 152: 2960-2967.
30. Broaddus VC, Hebert CA, Vitangcol RV, et al. Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyema. Am Rev Respir Dis 1992; 146: 825-830.
31. Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997; 10: 2411-2418.
32. Mohammed KA, Nasreen N, Antony VB. Bacterial induction of early response genes and activation of proapoptotic factors in pleural mesothelial cells. Lung 2007; 185: 355-365.
33. Idell S, Girard W, Koenig KB, et al. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991; 144: 187-194.
34. Mohammed KA, Nasreen N, Hardwick J, et al. Mycobacteria induces pleural mesothelial permeability by down-regulating beta-catenin expression. Lung 2003; 181: 57-66.
35. Mohammed KA, Nasreen N, Hardwick J, et al. Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001; 281: L119-L125.
36. Shetty S, John J, Idell S. Pleural fibrosis. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases. 2nd Edn. London, Hodder Arnold, 2009; pp. 101-112.
37. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med 2006; 119: 877-883.
38. Lindstrom ST, Kolbe J. Community acquired parapneumonic thoracic empyema: predictors of outcome. Respirology 1999; 4: 173-179.
39. Ruolff KL. Streptococcus. In: Murray PR, Baron EJ, Pfaller MA, et al., eds. Manual of Clinical Microbiology. 6th Edn. Washington, American Society for Microbiology, 1995; pp. 299-307.
40. Pratter MR, Irwin RS. Viridans streptococcal pulmonary parenchymal infections. JAMA 1980; 243: 2515-2517.
41. Sarkar TK, Murarka RS, Gilardi GL. Primary Streptococcus viridans pneumonia. Chest 1989; 96: 831-834.
42. Kobashi Y, Mouri K, Yagi S, et al. Clinical analysis of cases of empyema due to Streptococcus milleri group. Jpn J Infect Dis 2008; 61: 484-486.
43. Jerng JS, Hsueh PR, Teng LJ, et al. Empyema thoracis and lung abscess caused by viridans streptococci. Am J Respir Crit Care Med 1997; 156: 1508-1514.
44. Shinzato T, Saito A. A mechanism of pathogenicity of "Streptococcus milleri group" in pulmonary infection: synergy with an anaerobe. J Med Microbiol 1994; 40: 118-123.
45. Shinzato T, Saito A. The Streptococcus milleri group as a cause of pulmonary infections. Clin Infect Dis 1995; 21: Suppl. 3, S238-S243.
46. Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006; 174: 817-823.
47. Le Monnier A, Carbonnelle E, Zahar JR, et al. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. Clin Infect Dis 2006; 42: 1135-1140.
48. Saglani S, Harris KA, Wallis C, et al. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. Arch Dis Child 2005; 90: 70-73.
49. Darkes MJ, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs 2002; 4: 609-630.
50. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294: 2043-2051.
51. Dunais B, Bruno P, Carsenti-Dellamonica H, et al. Trends in nasopharyngeal carriage of Streptococcus pneumoniae among children attending daycare centers in southeastern France from 1999 to 2006. Pediatr Infect Dis J 2008; 27: 1033-1035.
52. Millar EV, O'Brien KL, Watt JP, et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006; 43: 8-15.
53. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-195.
54. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008; 47: 989-996.
55. Shafinoori S, Ginocchio CC, Greenberg AJ, et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J 2005; 24: 10-16.
56. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
57. Goldbart AD, Leibovitz E, Porat N, et al. Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine. Scand J Infect Dis 2009; 41: 182-187.
58. Bender JM, Ampofo K, Sheng X, et al. Parapneumonic empyema deaths during past century, Utah. Emerg Infect Dis 2009; 15: 44-48.
59. Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis 2002; 34: 434-440.
60. Hardie W, Bokulic R, Garcia VF, et al. Pneumococcal pleural empyemas in children. Clin Infect Dis 1996; 22: 1057-1063.
61. Buckingham SC, King MD, Miller ML. Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001. Pediatr Infect Dis J 2003; 22: 499-504.
62. Bekri H, Cohen R, Varon E, et al. Streptococcus pneumonia serotypes involved in children with pleural empyemas in France. Arch Pediatr 2007; 14: 239-243.
63. Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006; 25: 250-254.
64. Bartlett JG, Gorbach SL, Thadepalli H, et al. Bacteriology of empyema. Lancet 1974; 1: 338-340.
65. Koegelenberg CF, Diaconi AH, Bolligeri CT. Parapneumonic pleural effusion and empyema. Respiration 2008; 75: 241-250.
66. Chalmers JD, Singanayagam A, Murray MP, et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009; 64: 592-597.
67. Chen W, Lin YC, Liang SJ, et al. Hospital-acquired thoracic empyema in adults: a 5-year study. South Med J 2009; 6: 6.
68. Evans AL, Gleeson FV. Radiology in pleural disease: state of the art. Respirology 2004; 9: 300-312.
69. Wu RG, Yuan A, Liaw YS, et al. Image comparison of real-time gray-scale ultrasound and color Doppler ultrasound for use in diagnosis of minimal pleural effusion. Am J Respir Crit Care Med 1994; 150: 510-514.
70. Jones PW, Moyers JP, Rogers JT, et al. Ultrasound-guided thoracentesis: is it a safer method? Chest 2003; 123: 418-423.
71. Chen CH, Chen W, Chen HJ, et al. Transthoracic ultrasonography in predicting the outcome of small-bore catheter drainage in empyemas or complicated parapneumonic effusions. Ultrasound Med Biol 2009; 35: 1468-1474.
72. Kearney SE, Davies CW, Davies RJ, et al. Computed tomography and ultrasound in parapneumonic effusions and empyema. Clin Radiol 2000; 55: 542-547.
73. Roberts JR. Minimally invasive surgery in the treatment of empyema: intraoperative decision making. Ann Thorac Surg 2003; 76: 225-230.
74. Jaffe A, Calder AD, Owens CM, et al. Role of routine computed tomography in paediatric pleural empyema. Thorax 2008; 63: 897-902.
75. Calder A, Owens CM. Imaging of parapneumonic pleural effusions and empyema in children. Pediatr Radiol 2009; 39: 527-537.
76. Light RW, MacGregor MI, Ball WC Jr, et al. Diagnostic significance of pleural fluid pH and PCO2. Chest 1973; 64: 591-596.
77. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med 1980; 69: 507-512.
78. Porcel JM, Galindo C, Esquerda A, et al. Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions. Respirology 2008; 13: 58-62.
79. Heffner JE, Brown LK, Barbieri C, et al. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995; 151: 1700-1708.
80. Rahman NM, Mishra EK, Davies HE, et al. Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose. Am J Respir Crit Care Med 2008; 178: 483-490.
81. Porcel JM, Vives M, Cao G, et al. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 2009; 34: 1383-1389.
82. Lin MC, Chen YC, Wu JT, et al. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 2009; 136: 205-211.
83. Ferrer A, Osset J, Alegre J, et al. Prospective clinical and microbiological study of pleural effusions. Eur J Clin Microbiol Infect Dis 1999; 18: 237-241.
84. Maskell NA, Gleeson FV, Darby M, et al. Diagnostically significant variations in pleural fluid pH in loculated parapneumonic effusions. Chest 2004; 126: 2022-2024.
85. Davies CW, Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax 2003; 58: ii18-ii28.
86. Keeling AN, Leong S, Logan PM, et al. Empyema and effusion: outcome of image-guided small-bore catheter drainage. Cardiovasc Intervent Radiol 2008; 31: 135-141.
87. Akhan O, Ozkan O, Akinci D, et al. Image-guided catheter drainage of infected pleural effusions. Diagn Interv Radiol 2007; 13: 204-209.
88. Horsley A, Jones L, White J, et al. Efficacy and complications of small-bore, wire-guided chest drains. Chest 2006; 130: 1857-1863.
89. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58: Suppl. 1, i1-i94.
90. Davies HE, Rahman NM, Parker RJ, et al. Use of indwelling pleural catheters for chronic pleural infection. Chest 2008; 133: 546-549.
91. Simmers TA, Jie C, Sie B. Minimally invasive treatment of thoracic empyema. Thorac Cardiovasc Surg 1999; 47: 77-81.
92. Karmy-Jones R, Sorenson V, Horst HM, et al. Rigid thorascopic debridement and continuous pleural irrigation in the management of empyema. Chest 1997; 111: 272-274.
93. Chen KY, Liaw YS, Wang HC, et al. Sonographic septation: a useful prognostic indicator of acute thoracic empyema. J Ultrasound Med 2000; 19: 837-843.
94. Huang HC, Chang HY, Chen CW, et al. Predicting factors for outcome of tube thoracostomy in complicated parapneumonic effusion for empyema. Chest 1999; 115: 751-756.
95. Chin NK, Lim TK. Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions. Chest 1997; 111: 275-279.
96. Lee YC. Ongoing search for effective intrapleural therapy for empyema: is streptokinase the answer?Am J Respir Crit Care Med 2004; 170: 1-2.
97. Diacon AH, Theron J, Schuurmans MM, et al. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004; 170: 49-53.
98. Froudarakis ME, Kouliatsis G, Steiropoulos P, et al. Recombinant tissue plasminogen activator in the treatment of pleural infections in adults. Respir Med 2008; 102: 1694-1700.
99. Chen LE, Langer JC, Dillon PA, et al. Management of late-stage parapneumonic empyema. J Pediatr Surg 2002; 37: 371-374.
100. Chan DT, Sihoe AD, Chan S, et al. Surgical treatment for empyema thoracis: is video-assisted thoracic surgery "better" than thoracotomy? Ann Thorac Surg 2007; 84: 225-231.
101. Cardillo G, Carleo F, Carbone L, et al. Chronic postpneumonic pleural empyema: comparative merits of thoracoscopic versus open decortication. Eur J Cardiothorac Surg 2009; 36: 914-918.
102. Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174: 221-227.
103. Brutsche MH, Tassi GF, Gyorik S, et al. Treatment of sonographically stratified multiloculated thoracic empyema by medical thoracoscopy. Chest 2005; 128: 3303-3309.
104. Waller DA, Martin-Ucar AE. Surgery for pleural diseases. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases. 2nd Edn. London, Hodder Arnold, 2008; pp. 599-611.
105. Wait MA, Sharma S, Hohn J, et al. A randomized trial of empyema therapy. Chest 1997; 111: 1548-1551.
106. Bilgin M, Akcali Y, Oguzkaya F. Benefits of early aggressive management of empyema thoracis. ANZ J Surg 2006; 76: 120-122.
107. St Peter SD, Tsao K, Harrison C, et al. Thoracoscopic decortications vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. J Pediatr Surg 2009; 44: 106-111.
108. Nwiloh J, Freeman H, McCord C. Malnutrition: an important determinant of fatal outcome in surgically treated pulmonary suppurative disease. J Natl Med Assoc 1989; 81: 525-529.